Drug profile · INN
umeclidinium bromide
ANORO ELLIPTA (PREVIOUSLY ANORO)
umeclidinium bromide (ANORO ELLIPTA (PREVIOUSLY ANORO)) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — umeclidinium bromide
- US status
- approved
- Class
- Respiratory system (R03)
- Route
- INHALATION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
umeclidinium bromide (ANORO ELLIPTA (PREVIOUSLY ANORO)) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M3 antagonist
Primary target: Muscarinic acetylcholine receptor M3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is umeclidinium bromide?
umeclidinium bromide (ANORO ELLIPTA (PREVIOUSLY ANORO)) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for umeclidinium bromide?
ANORO ELLIPTA (PREVIOUSLY ANORO) is a marketed brand name for umeclidinium bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of umeclidinium bromide?
umeclidinium bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.